Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Amal Abdel-Baki, Émile Poulin, Sofia Medrano, Paula Pires de Oliveira Padilha, Emmanuel Stip & Stéphane Potvin. (2023) Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. International Journal of Psychiatry in Clinical Practice 27:1, pages 25-34.
Read now
Read now
Heidi C. Waters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel Rentería, A. John Rush, Rashmi Patel, Joydeep Sarkar, Heather M. Fitzgerald & Xue Han. (2023) Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study. Current Medical Research and Opinion 39:2, pages 299-306.
Read now
Read now
Wagner F Gattaz, Ricardo Saracco-Alvarez, Claudiane Salles Daltio, Martinus T Van de Bilt, Jose Julian Ortegón, Sergio J Villaseñor-Bayardo, Mario Louzã, Helio Elkis, Bernardo Soares, Patricia Cabrera Jaramillo, Fabio Lawson & Leonardo Díaz-Galvis. (2020) Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability. Neuropsychiatric Disease and Treatment 16, pages 2063-2072.
Read now
Read now
Rhiannon Kamstra, Dominic Pilon, Patrick Lefebvre, Bruno Emond & Kruti Joshi. (2018) Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. Current Medical Research and Opinion 34:8, pages 1377-1388.
Read now
Read now
Dominic Pilon, Kruti Joshi, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon L Kamstra, Bruno Emond & Patrick Lefebvre. (2017) Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Preference and Adherence 11, pages 619-629.
Read now
Read now
Takefumi Suzuki. (2016) A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opinion on Drug Delivery 13:2, pages 253-264.
Read now
Read now
Rene S Kahn & Amalia Giannopoulou. (2015) The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Review of Neurotherapeutics 15:9, pages 969-981.
Read now
Read now
Articles from other publishers (31)
Livio TARCHI, Francesco DEL MONACO, Diletta FALCONE, Andrea BALLERINI, Valdo RICCA & Giulio D’ANNA. (2023) Does occupational status predict symptomatic remission in outpatients with schizophrenia treated with long-acting antipsychotics? A 6-month follow-up study. Minerva Psychiatry 64:2.
Crossref
Crossref
Mauro Emilio Percudani, Rosaria Iardino, Matteo Porcellana, Jacopo Lisoni, Luisa Brogonzoli, Stefano Barlati & Antonio Vita. (2023) The Patient Journey of Schizophrenia in Mental Health Services: Results from a Co-Designed Survey by Clinicians, Expert Patients and Caregivers. Brain Sciences 13:5, pages 822.
Crossref
Crossref
Carla D. Cobb, Shari N. AllenJoseph M. CusimanoMichelle DingAmanda S. ElomaCarol A. OttKimberly B. Tallian. (2023) Social Determinants of Health in People Living with Psychiatric Disorders: The Role of Pharmacists. Health Equity 7:1, pages 223-234.
Crossref
Crossref
Alex Z. Fu, Jacqueline A. Pesa, Susan Lakey & Carmela Benson. (2022) Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry 22:1.
Crossref
Crossref
Chizimuzo T.C. Okoli, Amani Kappi, Tianyi Wang, Andrew Makowski & Andrew T. Cooley. (2021) The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis. International Journal of Mental Health Nursing 31:3, pages 469-535.
Crossref
Crossref
Lisa W. GoldstoneBethany A. DiPaulaAmy WerremeyerSheila BottsBrian HepburnHoward Y. LiuKen DuckworthAlexander S. YoungDeanna L. Kelly. (2021) The Role of Board-Certified Psychiatric Pharmacists in Expanding Access to Care and Improving Patient Outcomes. Psychiatric Services 72:7, pages 794-801.
Crossref
Crossref
Dee Lin, Philippe Thompson-Leduc, Isabelle Ghelerter, Ha Nguyen, Marie-Hélène Lafeuille, Carmela Benson, Panagiotis Mavros & Patrick Lefebvre. (2021) Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs 35:5, pages 469-481.
Crossref
Crossref
Silvio Curia, Feifei Ng, Marie-Emérentienne Cagnon, Victor Nicoulin & Adolfo Lopez-Noriega. (2021) Poly(ethylene glycol)-b-poly(1,3-trimethylene carbonate) Amphiphilic Copolymers for Long-Acting Injectables: Synthesis, Non-Acylating Performance and In Vivo Degradation. Molecules 26:5, pages 1438.
Crossref
Crossref
Omran Davarinejad, Tahereh Mohammadi Majd, Farzaneh Golmohammadi, Payam Mohammadi, Farnaz Radmehr, Mostafa Alikhani, Tayebeh Motaei, Mehdi Moradinazar, Annette Brühl, Dena Sadeghi Bahmani & Serge Brand. (2021) Identification of Risk Factors to Predict the Occurrences of Relapses in Individuals with Schizophrenia Spectrum Disorder in Iran. International Journal of Environmental Research and Public Health 18:2, pages 546.
Crossref
Crossref
Xiaobing Guo, Hongye Yu & Hu Wang. (2021) Antipsychotic patterns in outpatients with schizophrenia in China. Medicine 100:32, pages e26912.
Crossref
Crossref
Jeff Hrkach & Robert Langer. (2020) From micro to nano: evolution and impact of drug delivery in treating disease. Drug Delivery and Translational Research 10:3, pages 567-570.
Crossref
Crossref
Sosei Yamaguchi, Yasutaka Ojio, Junko Koike, Asami Matsunaga, Makoto Ogawa, Hisateru Tachimori, Akiko Kikuchi, Hiroshi Kimura, Ataru Inagaki, Hiroyuki Watanabe, Yoshiki Kishi, Koji Yoshida, Takaaki Hirooka, Satoru Oishi, Yasuhiro Matsuda & Chiyo Fujii. (2019) Associations between readmission and patient-reported measures in acute psychiatric inpatients: a study protocol for a multicenter prospective longitudinal study (the ePOP-J study). International Journal of Mental Health Systems 13:1.
Crossref
Crossref
Sandeep Grover, Swapnajeet Sahoo & Aseem Mehra. (2019) Perceptions of Psychiatrists Toward the Use of Long-Acting Injectable Antipsychotics. Journal of Clinical Psychopharmacology 39:6, pages 611-619.
Crossref
Crossref
Shobit Garg, Dhruv Gupta, Kislaya Rakesh & Sai Krishna Tikka. (2019) Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate. Journal of Clinical Psychopharmacology 39:5, pages 523-524.
Crossref
Crossref
Monica Aguilar & Benjamin Malcolm. (2019) Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study. Mental Health Clinician 9:4, pages 258-262.
Crossref
Crossref
Christoph Potempa & Reinhard Rychlik. (2018) Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany. Health Economics Review 8:1.
Crossref
Crossref
Kruti Joshi, Lian Mao, David M. Biondi & Robert Millet. (2018) The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia. BMC Psychiatry 18:1.
Crossref
Crossref
Marit Tveito, Robert L. Smith, Espen Molden, Tore Haslemo, Helge Refsum, Cecilie Hartberg, Christoph U. Correll & Gudrun Høiseth. (2018) Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations. Journal of Clinical Psychopharmacology 38:6, pages 570-576.
Crossref
Crossref
Seon-Cheol Park, Mi Young Choi, Jina Choi, Eunjung Park, Ha Jin Tchoe, Jae Kyung Suh, Young Hoon Kim, Seung Hee Won, Young-Chul Chung, Kyung-Yeol Bae, Sang-Kyu Lee, Chan Mi Park & Seung-Hwan Lee. (2018) Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis. Clinical Psychopharmacology and Neuroscience 16:4, pages 361-375.
Crossref
Crossref
Erika N. Titus-Lay, Elayne D. Ansara, Alex N. Isaacs & Carol A. Ott. (2018) Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Mental Health Clinician 8:2, pages 56-62.
Crossref
Crossref
Marie-Hélène Lafeuille, Neeta Tandon, Sean Tiggelaar, Rhiannon Kamstra, Patrick Lefebvre, Edward Kim, Yong Yue & Kruti Joshi. (2018) Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics. Drugs - Real World Outcomes 5:1, pages 81-90.
Crossref
Crossref
Chi-Un Pae, Sheng-Min Wang, Changsu Han, Won-Myong Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Alessandro Serretti & Robin Emsley. (2017) Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia. International Clinical Psychopharmacology 32:5, pages 235-248.
Crossref
Crossref
Seiya Miyamoto & W. Wolfgang Fleischhacker. (2017) The Use of Long-Acting Injectable Antipsychotics in Schizophrenia. Current Treatment Options in Psychiatry 4:2, pages 117-126.
Crossref
Crossref
Stanley Mutsatsa. (2017) The use of long-acting injectable antipsychotic medication. British Journal of Mental Health Nursing 6:3, pages 114-117.
Crossref
Crossref
Andrea Fagiolini, Paola Rocca, Serafino De Giorgi, Edoardo Spina, Giovanni Amodeo & Mario Amore. (2017) Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Research 247, pages 257-264.
Crossref
Crossref
. (2016) Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies. Drugs & Therapy Perspectives 33:1, pages 28-31.
Crossref
Crossref
Jung-Youl Park, Sujeong Shin, Jae-kwan Kim, Kyoung Chan Park & Jeong Ho Park. (2016) Synthesis of Benzoisoxazole Derivatives and Evaluation of Inhibitory Potency against Cholinesterase for Alzheimer's Disease Therapeutics. Bulletin of the Korean Chemical Society 37:9, pages 1464-1471.
Crossref
Crossref
Eduard Parellada & Miquel Bioque. (2016) Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. CNS Drugs 30:8, pages 689-701.
Crossref
Crossref
Jung-Youl Park, Sujeong Shin, Kyoung Chan Park, Eunju Jeong & Jeong Ho Park. (2016) Synthesis and in vitro Assay of New Triazole Linked Decursinol Derivatives Showing Inhibitory Activity against Cholinesterase for Alzheimer’s Disease Therapeutics. Journal of the Korean Chemical Society 60:2, pages 125-130.
Crossref
Crossref
Chelsie B. HeeschTroy A. Moore, Cynthia A. Gutierrez & Shuko Lee. (2016) Hospitalizations and emergency room visits after initiation of long-acting injectable antipsychotics. Mental Health Clinician 6:3, pages 134-141.
Crossref
Crossref
Jacqueline A. Pesa, Erik Muser, Leslie B. Montejano, David M. Smith & Oren I. Meyers. (2015) Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics. Drugs - Real World Outcomes 2:4, pages 377-385.
Crossref
Crossref